[1]郭桂玲,赵冰红.IgA-MM 患者血清双M 蛋白分析与实验室指标检测对骨髓移植疗效预测价值研究[J].现代检验医学杂志,2024,39(04):186-191+202.[doi:10.3969/j.issn.1671-7414.2024.04.034]
　GUO Guiling,ZHAO Binghong.Study on the Value of Serum Double M Protein Analysis and Laboratory Index Detection in Predicting the Curative Effect of Bone Marrow Transplantation in IgA-MM Patients[J].Journal of Modern Laboratory Medicine,2024,39(04):186-191+202.[doi:10.3969/j.issn.1671-7414.2024.04.034]
点击复制

IgA-MM 患者血清双M 蛋白分析与实验室指标检测对骨髓移植疗效预测价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
186-191+202
栏目:
检验与临床
出版日期:
2024-07-15

文章信息/Info

Title:
Study on the Value of Serum Double M Protein Analysis and Laboratory Index Detection in Predicting the Curative Effect of Bone Marrow Transplantation in IgA-MM Patients
文章编号:
1671-7414（2024）04-186-07
作者:
郭桂玲; 赵冰红
（中国人民解放军中部战区总医院检验科，武汉 430064）
Author(s):
GUO Guiling;  ZHAO Binghong
（Department of Clinical Laboratory, General Hospital of Central Theater Command, People’s Liberation Army, Wuhan 430064, China）
关键词:
免疫固定电泳; 双M 蛋白带; 免疫球蛋白A; 多发性骨髓瘤
分类号:
R733.3；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.04.034
文献标志码:
A
摘要:
目的 探讨IgA 型多发性骨髓瘤（IgA multiple myeloma，IgA-MM）患者血清双M 蛋白分析与实验室指标检测对骨髓移植疗效预测价值。方法 选择2019 年1 月~2022 年1 月于中国人民解放军中部战区总医院收治的60 例出现双M 条带的IgA-MM 患者为研究对象，比较患者血清蛋白电泳及免疫固定电泳（immunofixation electrophoresis，IFE）图谱资料；采用2- 巯基乙醇（2-dimercaptoethanol，2-DE）处理IgA-MM 双M 蛋白带的血清，IFE 鉴定双M 蛋白带；比较两种双M蛋白类型患者免疫学试验指标，包括免疫球蛋白A（immunoglobulin A，IgA）、免疫球蛋白G（immunoglobulinG，IgG）、免疫球蛋白M（immunoglobulin M，IgM）、血清游离轻链（serum free light chain，sFLC）和本周蛋白（Bene Jone protein，BJP）；并且比较二种双M 蛋白类型患者的常规实验指标；对两种IgA 型双M 蛋白血症骨髓瘤多发性骨髓瘤国际分期系统（international staging system，ISS）分期及疗效进行比较；采用Kaplan-Meier 法和LOGrank检验分析两种双M 蛋白类型的患者生存率。结果 IFE 显示，单克隆轻链型和IgA 聚合体型为IgA-MM 血清双M蛋白带的两种类型。单克隆轻链型患者相较于聚合体型sFLC（2 970.14±876.82 mg/L vs 118.68±74.10 mg/L）及BJP（6.22±3.01 g/L vs 0.55±0.12 g/L）水平更高，差异具有统计学意义（t=21.684,12.659，均P<0.05）；单克隆轻链型患者相较于聚合体型血清β2- 微球蛋白（β2-microglobulin，β2-MG）（7.88±2.14 mg/L vs 4.65±1.56 mg/L）、血清钙（calcium，Ca）（2.64±0.24 mmol/L vs 2.32±0.20 mmol/L）、肌酐（serum creatinine，Scr）（182.85±64.23 μmol/L vs90.52±42.20 μmol/L）水平升高（t=21.684，120.659，6.400，5.193，6.473），血红蛋白（hemoglobin，Hb）（74.32±19.44g/L vs 90.75±15.52 g/L）、清蛋白（albumin，Alb）（28.42±3.64 g/L vs 31.72±4.96 g/L）水平降低（t=3.386，2.428），差异具有统计学意义（均P<0.05）；与IgA 聚合体型患者相比，单克隆轻链型患者ISS 分期更高、疗效更低（t=11.827，4.519，均P<0.05）；生存分析结果显示，IgA 聚合体型相较于单克隆轻链型生存率更高（χ2=4.482，P<0.05）。结论 IgA 型双M 蛋白的两种类型在疗效和预后不尽相同，故鉴定IgA-MM 双M 蛋白带类型尤为重要。
Abstract:
Objective To investigate the value of serum double M protein analysis and laboratory index detection in predicting the efficacy of bone marrow transplantation in patients with IgA multiple myeloma (IgA-MM). Methods Sixty IgA-MM patients with double M bands admitted to the General Hospital of the Central Theater Command of the Chinese People’s Liberation Army from January 2019 to January 2022 were selected as the study objects. The chromatographic data of serum protein electrophoresis and immunofixation electrophoresis (IFE) were compared. Serum with double M protein bands of IgAMM was treated with 2-dimercaptoethanol (2-DE), and the double M protein bands were identified by IFE. Immunological test indexes of patients with two double M protein types were compared, including immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), serum free light chain (sFLC) and Bene Jone protein (BJP). The conventional experimental indexes of patients with two types of double M protein were compared. The staging and efficacy of multiple myeloma in the international staging system (ISS) were compared between two IgA types of double-M proteinemic myeloma. Kaplan-Meier method and LOG-rank test were used to analyze the survival rate of patients with two types of double M protein. Results IFE showed that monoclonal light chain type and IgA polymeric type were two types of double M protein bands in IGA-MM serum. Monoclonal light chain patients had higher levels of sFLC (2970.14±876.82 mg/L vs 118.68±74.10 mg/L) and BJP (6.22±3.01 g/L vs 0.55±0.12 g/L) than the polymeric type patients (t=21.684, 12.659, all P<0.05). Compared with polymeric type patients, serum β2-MG (β2-microglobulin) (7.88±2.14 mg/L vs 4.65±1.56 mg/L), serum Ca (calcium) (2.64±0.24 mmol/L vs 2.32±0.20 mmol/L) and serum Creatinine (Scr) (182.85±64.23 μmol/L vs 90.52±42.20 μmol/L) of monoclonal light chain patients were increased (t=21.684,12.659,6.400,5.193,6.473), while the levels of Hb (Hemoglobin) (74.32±19.44 g/L vs 90.75±15.52 g/L) and Alb (albumin) (28.42±3.64 g/L vs 31.72±4.96 g/L) of monoclonal light chain patients were decreased (t=3.386,2.428), with significant differences ( all P<0.05). Compared with IgA polymerized type patients, monoclonal light chain type patients had higher ISS stage and lower curative effect (t=11.827,4.519,all P<0.05). Survival analysis showed that the survival rate of IgA polymerized type was higher than that of monoclonal light chain type (χ2=4.482, P<0.05). Conclusion The two types of IgA-type double-M protein differed in efficacy and prognosis, so identifying the type of IgA-MM double M protein band may be particularly important.

参考文献/References:

[1] 蒋翔宁, 陈俊峰, 汪勇. 血清游离轻链κ/λ 比值联合免疫固定电泳在多发性骨髓瘤患者预后评估中的价值[J]. 中国实验血液学杂志, 2020, 28(1): 191-195. JIANG Xiangning, CHEN Junfeng, WANG Yong. Value of serum free light chain Kappa/Lambda ratio detection combined with immunofixation electrophoresis in the prognosis evaluation of patients with multiple myeloma[J]. Journal of Experimental Hematology, 2020, 28(1): 191-195.
[2] 范丽, 马艳萍, 晁瑶, 等. 老年多发性骨髓瘤肾损害患者的临床特征、预后及疗效分析[J]. 中国实验血液学杂志, 2021, 29(1): 145-151. FAN Li, MA Yanping, CHAO Yao, et al. Clinical characteristic, prognosis and treatment outcome of elderly multiple myeloma patients with impaired renal function[J]. Journal of Experimental Hematology, 2021, 29(1): 145-151.
[3] 喻垚, 滕小娟, 罗光丽, 等. 血清轻链在多发性骨髓瘤中的诊断及疗效评价中的价值[J]. 中国实验血液学杂志, 2020, 28(3): 886-893. YU Yao, TENG Xiaojuan, LUO Guangli, et al. Value of serum light chain in diagnosis and evaluation of efficacy for multiple myeloma[J]. Journal of Experimental Hematology, 2020, 28(3): 886-893.
[4] 蔡雨希, 易呈风, 罗礼容, 等. 多发性骨髓瘤合并贫血患者的临床特征及危险因素分析[J]. 重庆医学,2021, 50(4): 577-581. CAI Yuxi, YI Chengfeng, LUO Lirong, et al. Analysis of clinical characteristics and risk factors of multiple myeloma combined with anemia[J]. Chongqing Medicine, 2021, 50(4): 577-581.
[5] 张柳芸, 向云会, 李艳英, 等. M 蛋白在多发性骨髓瘤与淋巴瘤中的临床作用[J]. 中国实验血液学杂志,2022, 30(4): 1281-1285. ZHANG Liuyun, XIANG Yunhui, LI Yanying, et al. Clinical role of M protein in multiple myeloma and lymphoma-review[J]. Journal of Experimental Hematology, 2022, 30(4): 1281-1285.
[6] WHEELER R D, COSTA M V, CRICHLOW A, et al. Case report: interference from isatuximab on serum protein electrophoresis prevented demonstration of complete remission in a myeloma patient[J]. Annals of Clinical Biochemistry, 2022, 59(2): 144-148.
[7] THIRKETTLE S, RUSSELL J, WILSON S, et al. Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab[J]. Annals of Clinical Biochemistry, 2020, 57(2): 178-181.
[8] SCHNELLER A, ZOJER N, BOLOMSKY A, et al. Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma[J]. Haematologica, 2021, 106(9): 2516-2521.
[9] PERES L C, HANSEN D K, MAURA F, et al. The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S[J]. Seminars in Oncology, 2022, 49(1): 3-10.
[10] 张之南, 沈悌. 血液病诊断及疗效标准[M].3 版. 北京: 科学出版社, 2007. ZHANG Zhinan, SHEN Ti. Diagnosis and therapeutic effect criteria for hematological diseases[M]. 3th Ed. Beijing: Science Press, 2007.
[11] 龚盈盈, 闫晓爽, 王叶敏, 等. 多发性骨髓瘤患者的临床特征及预后因素分析[J]. 中国实验血液学杂志,2021, 29(3): 772-780. GONG Yingying, YAN Xiaoshuang, WANG Yemin, et al. Clinical features and prognostic factors of patients with multiple myeloma[J]. Journal of Experimental Hematology, 2021, 29(3): 772-780.
[12] ENGELHARDT M, TERPOS E, KLEBER M, et al. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma[J]. Haematologica, 2014, 99(2): 232-242.
[13] 杨光忠, 陈文明, 申曼, 等. BTD，MPT 方案序贯治疗新诊断的非移植多发性骨髓瘤患者的疗效分析[J]. 白血病·淋巴瘤, 2011, 20(6): 350-352. YANG Guangzhong, CHEN Wenming, SHEN Man, et al. Sequential therapy of BTD and MPT regimen for the newly-diagnosed multiple myeloma patients no eligible for bone marrow transplantation[J]. Journal of Leukemia & Lymphoma, 2011, 20(6): 350-352.
[14] LAI C, YING T, HO P J, et al. Successful kidney transplantation in a patient with stable multiple myeloma[J]. Internal Medicine Journal, 2020, 50(4): 492-494.
[15] KOBARI L, AUCLAIR M, PIAU O, et al. Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells[J]. Leukemia, 2022, 36(2): 540-548.
[16] SUN Mengtian, CHENG Jingliang, REN Cuiping, et al. Differentiation of diffuse infiltration pattern in multiple myeloma from hyperplastic hematopoietic bone marrow: qualitative and quantitative analysis using whole-body MRI[J]. Journal of Magnetic Resonance Imaging, 2022, 55(4): 1213-1225.
[17] SIM S, KALFF A, TUCH G, et al. The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia[J]. Internal Medicine Journal, 2023, 53(5): 819-824.
[18] O’DONNELL E K, SHAPIRO Y N, YEE A J, et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma[J]. Cancer, 2022, 128(10): 1996-2004.
[19] BANERJEE R, MIDHA S, KELKAR A H, et al. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma[J]. British Journal of Haematology, 2022, 196(5): 1274-1277.
[20] 任梅, 石培民, 谢静, 等. 血清CXCL9 和IL-34 水平检测对多发性骨髓瘤患者的疗效监测及其预后价值[J]. 现代检验医学杂志, 2023, 38(5): 127-132. REN Mei, SHI Peimin, XIE Jing, et al. Serum CXCL9 and IL-34 levels in multiple myeloma patients for monitoring efficacy and prognostic value[J]. Journal of Modern Laboratory Medicine, 2023, 38(5): 127-132.
[21] FACON T, VENNER C P, BAHLIS N J, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma[J]. Blood, 2021, 137(26): 3616-3628.
[22] LIU Jianfang, ZENG Piaoe, GUO Wei, et al. Prediction of high-risk cytogenetic status in multiple myeloma based on magnetic resonance imaging: utility of radiomics and comparison of machine learning methods[J]. Journal of Magnetic Resonance Imaging, 2021, 54(4): 1303-1311.
[23] SCHEUBECK S, IHORST G, SCHOELLER K, et al. Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort[J]. Cancer, 2021, 127(18): 3422-3436.
[24] HOU Yi, KUANG Wenbin, MIN Wenjian, et al. Design, synthesis, and biological evaluation of icaritin derivatives as novel putative DEPTOR inhibitors for multiple myeloma treatment[J]. Journal of Medicinal Chemistry, 2021, 64(20): 14942-14954.
[25] ER J, ROUTLEDGE D, HEMPTON J, et al. Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥ 65 years: a two-centre Australian experience[J]. Internal Medicine Journal, 2021, 51(2): 280-283.
[26] USMANI S Z, GARFALL A L, VAN DE DONK N W C J, et al. Teclistamab, a B-cell maturation antigen× CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study[J]. Lancet(London,England),2021, 398(10301): 665-674.
[27] PAWLYN C, LOEHR A, ASHBY C, et al. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?[J]. Leukemia, 2018, 32(7): 1561-1566.
[28] SOH K T, WALLACE P K . Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: current paradigm, guidelines, and future applications[J]. International Journal of Laboratory Hematology, 2021, 43（Suppl 1): 43-53.
[29] 高晓云, 马艳萍, 晁瑶, 等. IgD 型多发性骨髓瘤患者临床特征及生存分析[J]. 中国实验血液学杂志,2021, 29(2): 547-552. GAO Xiaoyun, MA Yanping, CHAO Yao, et al. Clinical characteristics and survival analysis of patients with IgD multiple myeloma[J]. Journal of Experimental Hematology, 2021, 29(2): 547-552.
[30] 陈明真, 张学亚, 王美娥, 等. 多发性骨髓瘤患者血脂指标水平及预后意义[J]. 中国实验血液学杂志,2022, 30(4): 1162-1169. CHEN Mingzhen, ZHANG Xueya, WANG Meie, et al. Serum lipid levels and their prognostic significance in patients with multiple myeloma[J].Journal of Experimental Hematology, 2022, 30(4): 1162-1169.
[31] 马柯娃, 孙超, 李建勇, 等. 多发性骨髓瘤预后因素的研究进展[J]. 中国实验血液学杂志, 2021, 29(4):1346-1350. MA Kewa, SUN Chao, LI Jianyong, et al. Research progress on prognostic factors of multiple myelomareview[J]. Journal of Experimental Hematology, 2021, 29(4): 1346-1350.
[32] 何人可, 王欣, 罗小华, 等. 自体造血干细胞移植治疗多发性骨髓瘤53 例的疗效评价及预后因素分析[J]. 第三军医大学学报, 2021, 43(6): 553-559. HE Renke, WANG Xin, LUO Xiaohua, et al. Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma:clinical analysis of 53 cases[J]. Journal of Third Military Medical University, 2021, 43(6): 553-559.
[33] ?EGULJA D, ?PARAKL T, ROGI? D. Applied capillary electrophoresis system affects screening for monoclonal gammopathy in serum: verification study of two eightcapillary systems[J]. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82(2): 85-89.
[34] KONISHI Y, SKLAVENITIS-PISTOFIDIS R, YUE Hong, et al. Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and waldenstrom macroglobulinemia[J]. Cancer Cell, 2022, 40(1): 6-8.
[35] DECHOW T, ALDAOUD A, BEHLENDORF T, et al. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials[J]. European Journal of Haematology, 2022, 108(2): 133-144.
[36] RI M, IIDA S, MARUYAMA D, et al. HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)[J]. Cancer Science, 2021, 112(12): 5011-5019.
[37] 李喆琪, 田卫伟, 郭雅芳, 等. 血清游离轻链比值及治疗后比值正常化对初诊多发性骨髓瘤患者诊断及预后的影响[J]. 中国实验血液学杂志, 2020, 28(4):1245-1250. LI Zheqi, TIAN Weiwei, GUO Yafang, et al. Effect of serum free light chain ratio and normalization ratio after treatment on diagnosis and prognosis of patients with newly diagnosed multiple myeloma[J]. Journal of Experimental Hematology, 2020, 28(4): 1245-1250.

备注/Memo

备注/Memo:
作者简介：郭桂玲（1986-），女，本科，中级技师，研究方向：多发性骨髓瘤，E-mail：455725323@qq.com。
通讯作者：赵冰红，女，硕士，副高级技师，研究方向：多发性骨髓瘤，E-mail：zhaobinghong0916@sina.com。
更新日期/Last Update: 2024-07-15